Entera Bio (NASDAQ:ENTX) Announces Earnings Results

Entera Bio (NASDAQ:ENTX) issued its earnings results on Friday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06), Zacks reports.

Entera Bio Price Performance

Shares of ENTX stock traded up $0.05 on Friday, hitting $2.87. The stock had a trading volume of 244,911 shares, compared to its average volume of 4,887,891. The company’s 50 day moving average price is $1.85 and its 200-day moving average price is $1.49. Entera Bio has a 1 year low of $0.91 and a 1 year high of $4.20. The firm has a market capitalization of $141.46 million, a P/E ratio of -10.63 and a beta of 1.38.

Institutional Trading of Entera Bio

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Superstring Capital Management LP purchased a new position in shares of Entera Bio in the fourth quarter valued at approximately $33,000. Citadel Advisors LLC increased its stake in Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after buying an additional 28,322 shares during the period. HighTower Advisors LLC lifted its holdings in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares in the last quarter. Jane Street Group LLC lifted its holdings in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after buying an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares in the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on ENTX. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $9.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.